Image Place holder

Sepideh Mokhtari, MD


Specialty: Neurology
Program: Neuro-Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Brain Cancer , Glioblastoma , Meningioma , Neurofibromatosis

Dr. Sepideh Mokhtari is an Associate Member in the Department of Neuro-Oncology at Moffitt Cancer Center. Dr. Mokhtari received her MD from Texas A&M College of Medicine in Temple, TX. She completed a Neurology Residency at Houston Methodist Hospital, where she also served as Chief Resident. She most recently completed a Neuro-Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Mokhtari’s clinical interests are primarily in brain tumors and neurologic complications of cancer. Her research focus is the quality of care for cancer patients with neurologic complications and primary brain tumors. In addition, her research interests include patients with meningioma and glioblastoma with or without other neurologic illness.

Education & Training

Board Certification:

  • Neurology
  • Psychiatry
  • Neuro-Oncology

Fellowship:

  • Memorial Sloan Kettering Cancer Center - Neuro-Oncology

Residency:

  • Houston Methodist Hospital - Neurology

Medical School:

  • Texas A&M - MD
Participating Trials

CLINICAL TRIAL 19433
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases
Condition:
Intervention: Avastin (Bevacizumab); Bevacizumab; Dexamethasone; Placebo; prednisone
Open

CLINICAL TRIAL 18880
A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 19385
A Randomized Phase 2 trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma who have not Received Prior VEGF Therapy
Condition:
Intervention: AZD2171 (Cediranib); Avastin (Bevacizumab); Bevacizumab; Cediranib (Recentin); FMISO; Olaparib (Lynparza)
Open

CLINICAL TRIAL 19339
A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases
Condition:
Intervention: AZD9291 (Osimertinib); Avastin (Bevacizumab); Bevacizumab
Open

CLINICAL TRIAL 19587
Neurofibroma and MPNST Tumor Progression in Neurofibromatosis Type 1 (NF1) -- Genomic, Histological and Clinical Analysis, an NF Research MPNST Genomic Consortium (GeM) Project: Part 2 -- Prospective Recruitment, Tissue Collection, and Analysis
Condition:
Intervention:
Open

CLINICAL TRIAL 19342
A Phase I Trial of Pembrolizumab and Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
Condition:
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Temodal (Temozolomide); Temozolomide; Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 19327
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases
Condition:
Intervention: Avastin (Bevacizumab); Bevacizumab; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18661
Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined with Nivolumab, Ipilimumab and Bevacizumab in Patients with Recurrent High Grade Gliomas
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun;169(2):391-396. Pubmedid: 29392582.
  • Sahebjam S, Stallworth DG, Mokhtari S, Tran ND, Arrington JA. Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors. Cancer Control. 2017 Apr;24(2):180-186. Pubmedid: 28441372.